Rep. April McClain Delaney Sells Off Shares of Bio-Techne Corp (NASDAQ:TECH)

Posted by Amy Steele on Mar 17th, 2026

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of Bio-Techne Corp (NASDAQ:TECH). In a filing disclosed on March 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bio-Techne stock on February 24th.

Representative April McClain Delaney also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of EMCOR Group (NYSE:EME) on 2/27/2026.
Sold $1,001 – $15,000 in shares of Jones Lang LaSalle (NYSE:JLL) on 2/27/2026.
Purchased $1,001 – $15,000 in shares of Nasdaq (NASDAQ:NDAQ) on 2/27/2026.
Sold $1,001 – $15,000 in shares of Morningstar (NASDAQ:MORN) on 2/25/2026.
Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 2/24/2026.
Sold $1,001 – $15,000 in shares of Jones Lang LaSalle (NYSE:JLL) on 2/24/2026.
Sold $1,001 – $15,000 in shares of CDW (NASDAQ:CDW) on 2/24/2026.
Sold $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/24/2026.
Sold $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/23/2026.
Purchased $15,001 – $50,000 in shares of Clean Harbors (NYSE:CLH) on 2/23/2026.

Bio-Techne Price Performance

NASDAQ TECH traded up $2.25 during trading hours on Tuesday, hitting $51.06. 2,447,692 shares of the company’s stock traded hands, compared to its average volume of 2,518,656. The company has a market capitalization of $7.99 billion, a PE ratio of 100.12, a PEG ratio of 3.38 and a beta of 1.48. The company has a debt-to-equity ratio of 0.13, a current ratio of 4.54 and a quick ratio of 3.08. Bio-Techne Corp has a 52-week low of $46.01 and a 52-week high of $72.16. The firm’s 50-day moving average is $61.95 and its 200-day moving average is $59.90.

Bio-Techne (NASDAQ:TECH – Get Free Report) last released its earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.03. The business had revenue of $295.88 million for the quarter, compared to analyst estimates of $290.20 million. Bio-Techne had a net margin of 6.67% and a return on equity of 13.94%. The business’s revenue was down .4% on a year-over-year basis. During the same period last year, the company posted $0.42 EPS. Equities analysts forecast that Bio-Techne Corp will post 1.67 EPS for the current fiscal year.

Bio-Techne Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, February 27th. Investors of record on Monday, February 16th were given a dividend of $0.08 per share. The ex-dividend date was Friday, February 13th. This represents a $0.32 dividend on an annualized basis and a yield of 0.6%. Bio-Techne’s payout ratio is presently 62.75%.

Analyst Ratings Changes

TECH has been the topic of a number of analyst reports. Citigroup reiterated a “buy” rating and set a $80.00 price objective (up from $70.00) on shares of Bio-Techne in a research report on Wednesday, February 4th. Stifel Nicolaus set a $65.00 target price on Bio-Techne and gave the stock a “hold” rating in a research note on Thursday, February 5th. UBS Group reiterated a “buy” rating and set a $79.00 price target (up from $70.00) on shares of Bio-Techne in a report on Thursday, February 5th. Wells Fargo & Company boosted their price target on shares of Bio-Techne from $70.00 to $76.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Finally, Robert W. Baird set a $70.00 price objective on shares of Bio-Techne in a report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, Bio-Techne presently has a consensus rating of “Moderate Buy” and an average price target of $72.77.

View Our Latest Stock Report on TECH

Institutional Investors Weigh In On Bio-Techne

Institutional investors have recently made changes to their positions in the stock. Blue Trust Inc. raised its position in Bio-Techne by 109.7% in the third quarter. Blue Trust Inc. now owns 453 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 237 shares during the period. Danske Bank A S purchased a new position in shares of Bio-Techne during the fourth quarter worth $29,000. eCIO Inc. acquired a new stake in shares of Bio-Techne in the fourth quarter valued at $30,000. Allworth Financial LP grew its stake in shares of Bio-Techne by 68.1% in the second quarter. Allworth Financial LP now owns 612 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 248 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC purchased a new stake in shares of Bio-Techne in the 3rd quarter valued at $32,000. 98.95% of the stock is currently owned by institutional investors and hedge funds.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Bio-Techne Company Profile

(Get Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.